EGFR and central nervous system cancer: Novel pathogenesis-based treatments targeting oncogenic signaling pathways such as BRAF mutation (Robinson et al., 2014), epidermal growth factor receptor (EGFR) amplification (Phillips et al., 2016), and fibroblast growth factor receptor (FGFR)-TACC fusion demonstrate a potential for lower grade gliomas (LGG) elimination (Stefano et al., 2015).